An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007)

Lundbeck

Status and phase: Withdrawn; Phase 3

Conditions: Insomnia

Treatments: Drug: MK0928, gaboxadol / Duration of Treatment: 10 months

Study type: Interventional

Funder types: Industry

Identifiers

NCT00102154

2004_093

0928-007

Details and patient eligibility

About

A study to evaluate the safety and effectiveness of an investigational drug for insomnia (a sleep disorder).

Sex: All

Ages: 18 to 64 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy adults who are between the ages of 18 and 64

Exclusion criteria

• Adults who are diagnosed with insomnia

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind